DEST to present at Shares & AJ Bell Webinar 6/7/21

RNS Number : 4596D
Destiny Pharma PLC
29 June 2021
 

Destiny Pharma plc

 

("Destiny Pharma" or "the Company")

 

Destiny Pharma to present at the Shares and AJ Bell Investor Webinar on 06 July 2021

 

Brighton, United Kingdom - 29 June 2021 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that its Chief Executive Officer, Neil Clark, will provide a live presentation on the Company at the Shares and AJ Bell Investor Evening Webinar on Tuesday, 06 July at 6:00 pm BST.

 

The Shares and AJ Bell Investor Evening Webinar is an opportunity for existing and potential investors to receive a business update from senior executives of listed PLCs.

 

Attendees will have the opportunity to ask questions to the presenters via an online chat window during the webinar.

 

Shareholders and potential investors can register to join the webinar for free at:

https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-060721

 

 

-ENDS-

 

 

For further information, please contact: 

 

Destiny Pharma plc 

Neil Clark, CEO 

Shaun Claydon, CFO 

+44 (0) 1273 704 440 

pressoffice@destinypharma.com  

 

Optimum Strategic Communications 

Mary Clark/ Hollie Vile/ Manel Mateus

+44 (0) 203 174 1789

destinypharma@optimumcomms.com  

 

About Destiny Pharma plc

Destiny Pharma is a UK based, clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence, which is the leading cause of hospital acquired infection in the US, and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections, and has earlier grant funded XF research projects. 

 

For further information on the company, please visit  https://www.destinypharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPPUPPQUPGUMB
UK 100

Latest directors dealings